Literature DB >> 28611535

Biological Subtypes of Triple-Negative Breast Cancer.

Michael Hubalek1, Theresa Czech2, Hannes Müller2.   

Abstract

Triple-negative breast cancers (TNBCs) are defined as tumors that are negative for estrogen, progesterone and HER-2 receptor. At a percentage of 10-20% TNBCs represent a minority in all breast cancers. However, because of the poor prognosis this particular subtype, triple negative disease accounts for a disproportionate number of metastatic cases and breast cancer deaths. Identification of its subtypes is essential for understanding the biological characteristics and clinical behavior of TNBC, as well as for developing personalized treatments. This review will focus on the great progress that has been made in the past few years on identifying new targets in TNBC subtypes and a variety of new treatment options that are on the verge of routine clinical application.

Entities:  

Keywords:  Biological activity; Breast cancer; Subtypes; Triple-negative

Year:  2017        PMID： 28611535      PMCID： PMC5465739          DOI： 10.1159/000455820

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


  49 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Molecular stratification of triple-negative breast cancers.

Authors:  Charles M Perou
Journal:  Oncologist       Date:  2011

3.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.

Authors:  M Esteller; J M Silva; G Dominguez; F Bonilla; X Matias-Guiu; E Lerma; E Bussaglia; J Prat; I C Harkes; E A Repasky; E Gabrielson; M Schutte; S B Baylin; J G Herman
Journal:  J Natl Cancer Inst       Date:  2000-04-05       Impact factor: 13.506

4.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Authors:  Gunter von Minckwitz; Andreas Schneeweiss; Sibylle Loibl; Christoph Salat; Carsten Denkert; Mahdi Rezai; Jens U Blohmer; Christian Jackisch; Stefan Paepke; Bernd Gerber; Dirk M Zahm; Sherko Kümmel; Holger Eidtmann; Peter Klare; Jens Huober; Serban Costa; Hans Tesch; Claus Hanusch; Jörn Hilfrich; Fariba Khandan; Peter A Fasching; Bruno V Sinn; Knut Engels; Keyur Mehta; Valentina Nekljudova; Michael Untch
Journal:  Lancet Oncol       Date:  2014-04-30       Impact factor: 41.316

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.

Authors:  Fabrice Andre; Bastien Job; Philippe Dessen; Attila Tordai; Stefan Michiels; Cornelia Liedtke; Catherine Richon; Kai Yan; Bailang Wang; Gilles Vassal; Suzette Delaloge; Gabriel N Hortobagyi; W Fraser Symmans; Vladimir Lazar; Lajos Pusztai
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

7.  Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.

Authors:  Neelima Denduluri; Mark R Somerfield; Andrea Eisen; Jamie N Holloway; Arti Hurria; Tari A King; Gary H Lyman; Ann H Partridge; Melinda L Telli; Maureen E Trudeau; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2016-04-18       Impact factor: 44.544

Review 8.  Hallmarks of 'BRCAness' in sporadic cancers.

Authors:  Nicholas Turner; Andrew Tutt; Alan Ashworth
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

9.  Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival.

Authors:  Victor J Weigman; Hann-Hsiang Chao; Andrey A Shabalin; Xiaping He; Joel S Parker; Silje H Nordgard; Tatyana Grushko; Dezheng Huo; Chika Nwachukwu; Andrew Nobel; Vessela N Kristensen; Anne-Lise Børresen-Dale; Olufunmilayo I Olopade; Charles M Perou
Journal:  Breast Cancer Res Treat       Date:  2011-11-03       Impact factor: 4.872

Review 10.  Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.

Authors:  Aniello Cerrato; Francesco Morra; Angela Celetti
Journal:  J Exp Clin Cancer Res       Date:  2016-11-24
View more
  29 in total

1.  Therapeutic Strategies in Triple-Negative Breast Cancer.

Authors:  Angelo Paradiso; Christian F Singer
Journal:  Breast Care (Basel)       Date:  2017-02-28       Impact factor: 2.860

2.  Role of Capecitabine in Early Breast Cancer.

Authors:  Asya N Varshavsky-Yanovsky; Lori J Goldstein
Journal:  J Clin Oncol       Date:  2019-12-05       Impact factor: 44.544

3.  Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma.

Authors:  Hulya Sahin Ozkan; Mustafa Umit Ugurlu; Perran Fulden Yumuk; Handan Kaya
Journal:  Pathol Oncol Res       Date:  2020-07-17       Impact factor: 3.201

4.  A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer.

Authors:  Rachel L Stewart; Katherine L Updike; Rachel E Factor; N Lynn Henry; Kenneth M Boucher; Philip S Bernard; Katherine E Varley
Journal:  Cancer Res       Date:  2019-05-02       Impact factor: 12.701

Review 5.  Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC).

Authors:  Aiswarya Chaudhuri; Dulla Naveen Kumar; Deepa Dehari; Sanjay Singh; Pradeep Kumar; Pradeep Kumar Bolla; Dinesh Kumar; Ashish Kumar Agrawal
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-27

Review 6.  Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line.

Authors:  Citra Dewi; Adryan Fristiohady; Riezki Amalia; Nur Kusaira Khairul Ikram; Sugeng Ibrahim; Muchtaridi Muchtaridi
Journal:  Molecules       Date:  2022-06-07       Impact factor: 4.927

Review 7.  Epithelial-to-Mesenchymal Transition Signaling Pathways Responsible for Breast Cancer Metastasis.

Authors:  Busra Buyuk; Sha Jin; Kaiming Ye
Journal:  Cell Mol Bioeng       Date:  2021-09-02       Impact factor: 3.337

8.  α-Santalol functionalized chitosan nanoparticles as efficient inhibitors of polo-like kinase in triple negative breast cancer.

Authors:  Jinku Zhang; Yanan Wang; Jinmei Li; Wenming Zhao; Zhao Yang; Yanguang Feng
Journal:  RSC Adv       Date:  2020-02-03       Impact factor: 4.036

9.  The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts.

Authors:  Yan Zhong; Lin Deng; Shuo Shi; Qiu-Yao Huang; Shu-Min Ou-Yang; Jian-Shan Mo; Kai Zhu; Xin-Ming Qu; Pei-Qing Liu; Yuan-Xiang Wang; Xiao-Lei Zhang
Journal:  Acta Pharmacol Sin       Date:  2021-07-15       Impact factor: 6.150

10.  Triple Negative Breast Cancer Depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-Phosphate Receptor 3 (S1PR3)/Notch Signaling for Metastasis.

Authors:  Shushu Wang; Yueyang Liang; Wenxiao Chang; Baoquan Hu; Yi Zhang
Journal:  Med Sci Monit       Date:  2018-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.